PRISMASOL 2 Solution

দেশ: কানাডা

ভাষা: ফরাসি

সূত্র: Health Canada

সক্রিয় উপাদান:

Chlorure de calcium; Chlorure de magnésium; Dextrose anhydre; L-Acide lactique; Chlorure de sodium; Bicarbonate de sodium; Chlorure de potassium

থেকে পাওয়া:

BAXTER CORPORATION

এটিসি কোড:

B05ZA

INN (আন্তর্জাতিক নাম):

HEMODIALYTICS, CONCENTRATES

ডোজ:

5.145G; 2.033G; 22.00G; 5.400G; 6.450G; 3.090G; 0.157G

ফার্মাসিউটিকাল ফর্ম:

Solution

রচনা:

Chlorure de calcium 5.145G; Chlorure de magnésium 2.033G; Dextrose anhydre 22.00G; L-Acide lactique 5.400G; Chlorure de sodium 6.450G; Bicarbonate de sodium 3.090G; Chlorure de potassium 0.157G

প্রশাসন রুট:

Intraveineuse

প্যাকেজ ইউনিট:

250ML+4750ML 2 CHAMBER BAG

প্রেসক্রিপশন টাইপ:

Spécialité médicale

থেরাপিউটিক এলাকা:

HEMODIALYSIS SOLUTION

পণ্য সারাংশ:

Numéro de groupe d'ingrédients actifs (GIA) :0752650001; AHFS:

অনুমোদন অবস্থা:

APPROUVÉ

অনুমোদন তারিখ:

2014-12-31

পণ্য বৈশিষ্ট্য

_ _
_PrismaSOL 4 mmol/l Potassium _
_Page 1 of 22_
PRESCRIBING INFORMATION
PRISMASOL 4
Calcium chloride dihydrate 5.145 g/L, Glucose anhydrous 22.0 g/L,
Lactic acid 5.4g/L,
Magnesium chloride hexahydrate 2.033 g/L, Potassium chloride 0.314
g/L, Sodium bicarbonate
3.090 g/L, and Sodium chloride 6.45 g/L solution
Sterile solution for hemofiltration and hemodialysis
Hemodialytics, concentrates, ATC code: B05Z A
BAXTER CORPORATION
MISSISSAUGA, ON
CANADA, L5N 0C2
Date of Initial Approval:
February 21, 2006
Date of Preparation:
February 26, 2019
Submission Control No: 218874
Baxter and PrismaSOL are trademarks of Baxter International Inc., or
its subsidiaries.
_ _
_PrismaSOL 4 _
_Page 2 of 22_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................6
DRUG INTERACTIONS
....................................................................................................7
DOSAGE AND ADMINISTRATION
................................................................................9
OVERDOSAGE
................................................................................................................10
ACTION AND CLINICAL PHARMACOLOGY
............................................................10
STORAGE AND STABILITY
..........................................................................................11
SPECIAL HANDLING INSTRUCTIONS
.......................................................................12
DOSAGE